We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Increased Risk of Death Seen With Advair, Serevent, Foradil
Increased Risk of Death Seen With Advair, Serevent, Foradil
June 13, 2006
A recently published study says long-acting bronchodilators — also known as long-acting beta-agonists (LABAs) — should be pulled off the market because patients are four to six times more likely to die from asthma symptoms and were hospitalized twice as often as patients on placebos, a finding that could affect future sales of generic versions of these drugs.